- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Financial analysis and consensus estimates detail the competitive GLP-1 market between Eli Lilly and Novo Nordisk.
Eli Lilly's Tirzepatide is driving 65% of the company's revenue amid intense competition in the GLP-1 market.
3 reports, 2 independent
Updated Sep 9
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly's Tirzepatide is driving 65% of the company's revenue amid intense competition in the GLP-1 market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
Related events
- FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly and Kailera Therapeutics are competing in the obesity treatment market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.